Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors, results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated individuals. The relative contribution of afterload toward inducing cardiac dysfunction with sunitinib treatment remains unknown. We created a preclinical model of sunitinib cardiotoxicity using engineered microtissues that exhibited cardiomyocyte death, decreases in force generation, and spontaneous beating at clinically relevant doses. Simulated increases in afterload augmented sunitinib cardiotoxicity in both rat and human microtissues, which suggest that antihypertensive therapy may be a strategy to prevent left ventricular dysfunction in patients treated with sunitinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 2×
“Displacement d ðmmÞ 1⁄4 ðB ðSþ 4ÞÞ 0:1706 pixels mm (1)”
BackgroundAnimal Models of Heart Failure: A Scientific Statement From the American Heart Association
Houser, S. R., Margulies, K. B., Murphy, A. M., Spinale, F. G., Francis, G. S., Prabhu, S. D., Rockman, H. A., Kass, D. A., Molkentin, J. D., Sussman, M. A., et al. (2012) · Circulation Research · doi:10.1161/res.0b013e3182582523 · Cited by 435
Self-citationBoudou, T., Legant, W. R., Mu, A., Borochin, M. A., Thavandiran, N., Radisic, M., Zandstra, P. W., Epstein, J. A., Margulies, K. B., & Chen, C. S. (2012) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0341 · Cited by 413
Self-citationAssessment of left ventricular function in aortic stenosis
Ozkan, A., Kapadia, S., Tuzcu, M., & Marwick, T. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.80 · Cited by 57
Cited by
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis
Bailey, A. L., Dmytrenko, O., Greenberg, L., Bredemeyer, A. L., Ma, P., Liu, J., Penna, V., Winkler, E. S., Sviben, S., Brooks, E., et al. (2021) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2021.01.002 · Cited by 193
Cardiac Tissues From Stem Cells: New Routes to Maturation and Cardiac Regeneration
Campostrini, G., Windt, L. M., van Meer, B. J., Bellin, M., & Mummery, C. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318183 · Cited by 96
Liver–heart on chip models for drug safety
Ferrari, E., & Rasponi, M. (2021) · APL Bioengineering · doi:10.1063/5.0048986 · Cited by 53
Liu, S., Fang, C., Zhong, C., Li, J., & Xiao, Q. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09835-4 · Cited by 22
“Rachel Truitt et al. first investigated sunitinib-induced cardiotoxicity using a 3D engineered tissue platform and found that antihypertensive therapy could reduce the incidents of left ventricular dysfunction during TKIs treatment(Truitt et al. 2018).”
MethodBiotechnological advances and applications of human pluripotent stem cell-derived heart models
Muniyandi, P., O’Hern, C., Popa, M. A., & Aguirre, A. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1214431 · Cited by 14
Metadata
- Authors
- Truitt, R., Mu, A., Corbin, E. A., Vite, A., Brandimarto, J., Ky, B., & Margulies, K. B.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 3
- Issue
- 2
- Pages
- 265-276
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W2801312657
- Cited by
- 56
- References
- 5
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.